CD4 and cancer: These results indicate that dexamethasone enhanced anti-tumor effect of ICIs is dependent on the activity of T cells, which is regulated by the decreased PD-L1 and IDO1 on cancer cells and PD-L1 on CD4+ T cells (Fig. 6F).